Overall survival analysis of COU-AA-301

Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer.

We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castrationresistant prostate cancer who have received chemotherapy.

The combination of the mTOR inhibitor everolimus with the aromatase inhibitor exemestane was evaluated in the randomized Phase III BOLERO-2 trial.

Research has indicated that aberrant signaling through the mTOR pathway is associated with resistance to endocrine therapies.

Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resistance to endocrine therapy results in disease progression in a large proportion of breast cancers.

Through the understanding of the mechanisms of endocrine resistance, identification of implicated pathways and targets has led to the development of novel agents targeting these pathways.